Childhood Cancer Predisposition Study (CCPS)
Study Details
Study Description
Brief Summary
The Childhood Cancer Predisposition Study (CCPS) is a multi-center, longitudinal, observational study that will collect clinical and biological data and specimens from children with a cancer predisposition syndromes (CPS) and their relatives.
The central hypothesis is that studying individuals at high risk for childhood cancer creates a unique opportunity for improving the understanding of carcinogenesis, tumor surveillance, early detection, and cancer prevention, which will collectively contribute to improving care and outcomes for pediatric patients with cancer and those with cancer predisposition syndromes (CPS).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The CCPS is designed as a multi-center, longitudinal, observational study that will collect clinical and biological data and specimens from children with a CPS and their relatives. The investigators plan to:
-
Establish and maintain a framework for recruitment, participation, and surveillance of children with cancer predisposition syndromes (CPS) in clinical and translational research studies;
-
Define the natural history of disease in children with CPS; and
-
Evaluate the clinical impact and effectiveness of standard and emerging tumor surveillance strategies.
The study will enroll approximately 350 Children and 700 Relatives per year. The investigators plan to collect demographic and diagnostic data at enrollment. Longitudinal follow-up will be performed at least annually.
The CCPS includes the establishment of a biorepository, with a hub and spoke structure, with a central repository at Emory University/Children's Healthcare of Atlanta for prospective collection of some tissues, linked to local biorepositories at participating institutions. Information about inventory of tumor specimens already banked locally will be available in the database, along with reference to existing genomic studies of the tumor, such that investigators may identify and request such tissue or data for specific studies, subject to approval of the CCPS Scientific Committee.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Primary Subjects Children (age 0-21) with a cancer predisposition syndromes (CPS). |
Other: Registry
This prospective registry and biorepository will collect clinical data and specimens for research in childhood cancer predisposition.
|
| Relatives of Children with CPS Members of their Primary Family Unit will also be recruited for this study, including CPS-Affected Parents, Unaffected Parents and Siblings. Other adult family members (with documented or obligate CPS) are also eligible to enroll as Affected Family Members. |
Other: Registry
This prospective registry and biorepository will collect clinical data and specimens for research in childhood cancer predisposition.
|
Outcome Measures
Primary Outcome Measures
- Establish and maintain a framework for recruitment, participation, and surveillance of children with cancer predisposition syndromes (CPS) in clinical and translational research studies. [Up to 10 years]
This multicenter registry and biorepository will be developed with the purpose of studying individuals at high risk for childhood cancer to improve care and outcomes for pediatric patients with cancer and those with cancer predisposition syndromes (CPS).
- Define the natural history of disease in children with CPS. [Up to 10 years]
To define the natural history of disease in children with CPS.
- Evaluate the clinical impact and effectiveness of standard and emerging tumor surveillance strategies. [Up to 10 years]
Evaluate the clinical impact and effectiveness of standard and emerging tumor surveillance strategies to improve care and outcomes for pediatric patients with cancer and those with cancer predisposition syndromes (CPS).
Eligibility Criteria
Criteria
Inclusion Criteria:
Primary Subjects must meet all of the below criteria to be eligible for enrollment:
-
Be less than 21 years of age at the time of enrollment
-
Have a diagnosis of a specific CPS, whether they have had cancer or not
-
Based on clinical laboratory testing demonstrating a Pathogenic or Likely Pathogenic germline variant and/or
-
Based on well-established clinical diagnostic criteria and/or
-
Based on high clinical suspicion of a specific CPS with clinical laboratory testing demonstrating a variant of uncertain significance (VUS)
Affected Parents must meet all of the following criteria to be eligible for enrollment:
-
Be the biologic parent of a Primary Subject and
-
Carry a diagnosis (or obligate diagnosis) of the familial CPS
Adult Affected Siblings must meet all of the following criteria to be eligible for enrollment:
-
Be the biologic sibling of a Primary Subject and
-
Carry a diagnosis (or obligate diagnosis) of the familial CPS
Unaffected Parents and Siblings must meet all of the following criteria to be eligible for enrollment
-
Be the biologic parent or sibling of a Primary Subject and
-
Not carry a diagnosis (or obligate diagnosis) of the familial CPS
Affected Family Members must meet all of the following criteria to be eligible for enrollment:
- Carry a diagnosis of (or obligate diagnosis of) the familial CPS. Documentation is requested but not required.
More than one child from a Primary Family Unit may be a Primary Subject. An Unaffected Sibling may be reclassified as a Primary Subject if diagnosed with a CPS during childhood.
Exclusion Criteria:
- Individuals with a strong personal or family history of cancer without a genetic or clinical diagnosis of a specific CPS are not eligible for enrollment.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Children's Healthcare of Atlanta (CHOA) | Atlanta | Georgia | United States | 30322 |
| 2 | Dana Farber Cancer Institute | Boston | Massachusetts | United States | 02215 |
| 3 | Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | United States | 19104 |
| 4 | St. Jude Children's Research Hospital | Memphis | Tennessee | United States | 38105-3678 |
| 5 | Baylor College of Medicine | Houston | Texas | United States | 77030 |
| 6 | Primary Children's Hospital | Salt Lake City | Utah | United States | 84113 |
| 7 | Hospital for Sick Children | Toronto | Ontario | Canada |
Sponsors and Collaborators
- Emory University
Investigators
- Principal Investigator: Christopher Porter, MD, Emory University
- Principal Investigator: Anita Villani, MD, The Hospital for Sick Children
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- STUDY00000109
- C3P-001